HEAT INACTIVATION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE-2 (HIV-2)

被引：5
|
作者：
GREGERSEN, JP [1 ]
HILFENHAUS, J [1 ]
LEMP, JF [1 ]
机构：
[1] ELECTRO NUCLEON INC,INST CELL SCI,SILVER SPRING,MD 20904
来源：
JOURNAL OF BIOLOGICAL STANDARDIZATION | 1989年 / 17卷 / 04期
关键词：
D O I：
10.1016/S0092-1157(89)80009-5
中图分类号：
Q [生物科学];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
引用
收藏
页码：377 / 379
页数：3
相关论文
共 50 条
  • [21] PREVALENCE AND RISK DETERMINANTS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-2 (HIV-2) AND HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1) IN WEST AFRICAN FEMALE PROSTITUTES
    KANKI, P
    MBOUP, S
    MARLINK, R
    TRAVERS, K
    HSIEH, CC
    GUEYE, A
    BOYE, C
    SANKALE, JL
    DONNELLY, C
    LEISENRING, W
    SIBY, T
    THIOR, I
    DIA, M
    GUEYE, EH
    NDOYE, I
    ESSEX, M
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 1992, 136 (07) : 895 - 907
  • [22] Binding properties of human immunodeficiency virus type-2 (HIV-2) RNA corresponding to the packaging signal to its nucleocapsid protein
    Tsukahara, T
    Komatsu, H
    Kubo, M
    Obata, F
    Tozawa, H
    BIOCHEMISTRY AND MOLECULAR BIOLOGY INTERNATIONAL, 1996, 40 (01): : 33 - 42
  • [23] HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-2 (HIV-2) TRANSACTIVATOR (TAT) - FUNCTIONAL DOMAINS AND THE SEARCH FOR TRANSDOMINANT NEGATIVE MUTANTS
    ARYA, SK
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1993, 9 (09) : 839 - 848
  • [24] CLINICAL, HEMATOLOGIC, AND IMMUNOLOGICAL CROSS-SECTIONAL EVALUATION OF INDIVIDUALS EXPOSED TO HUMAN IMMUNODEFICIENCY VIRUS TYPE-2 (HIV-2)
    MARLINK, RG
    RICARD, D
    MBOUP, S
    KANKI, PJ
    ROMETLEMONNE, JL
    NDOYE, I
    DIOP, K
    SIMPSON, MA
    GRECO, F
    CHOU, MJ
    DEGRUTTOLA, V
    HSIEH, CC
    BOYE, C
    BARIN, F
    DENIS, F
    MCLANE, MF
    ESSEX, M
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1988, 4 (02) : 137 - 148
  • [25] DIDEOXYNUCLEOSIDES ARE LESS INHIBITORY INVITRO AGAINST HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-2 (HIV-2) THAN AGAINST HIV-1
    RICHMAN, DD
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (12) : 1879 - 1881
  • [26] Human Immunodeficiency Virus Type 2 (HIV-2) EU-Supporting Standardized HIV-2 Drug Resistance Interpretation: An Update
    Charpentier, Charlotte
    Berzow, Dirk
    Le Hingrat, Quentin
    Kaiser, Rolf
    Gomes, Perpetua
    Miranda, Ana Claudia
    Damond, Florence
    Ghosn, Jade
    van Kampen, Jeroen J. A.
    Jensen, Bjoern-Erik Ole
    Boehm, Michael
    Wensing, Annemarie M. J.
    Descamps, Diane
    Obermeier, Martin
    CLINICAL INFECTIOUS DISEASES, 2025,
  • [27] MOLECULAR AND BIOLOGICAL CHARACTERIZATION OF A REPLICATION COMPETENT HUMAN IMMUNODEFICIENCY TYPE-2 (HIV-2) PROVIRAL CLONE
    FRANCHINI, G
    FARGNOLI, KA
    GIOMBINI, F
    JAGODZINSKI, L
    DEROSSI, A
    BOSCH, M
    BIBERFELD, G
    FENYO, EM
    ALBERT, J
    GALLO, RC
    WONGSTAAL, F
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (07) : 2433 - 2437
  • [28] Computational studies of inhibitor binding to human immunodeficiency virus, Type 2 (HIV-2) protease
    Summay, Russell
    Waingeh, Victor
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 249
  • [29] Variability of human immunodeficiency virus type 2 (HIV-2) infecting patients living in France
    Damond, F
    Apetrei, C
    Robertson, DL
    Souquière, S
    Leprêtre, A
    Matheron, S
    Plantier, JC
    Brun-Vézinet, F
    Simon, F
    VIROLOGY, 2001, 280 (01) : 19 - 30
  • [30] INFECTION OF BABOONS WITH HUMAN IMMUNODEFICIENCY VIRUS-2 (HIV-2)
    LETVIN, NL
    DANIEL, MD
    SEHGAL, PK
    YETZ, JM
    SOLOMON, KR
    KANNAGI, M
    SCHMIDT, DK
    SILVA, DP
    MONTAGNIER, L
    DESROSIERS, RC
    JOURNAL OF INFECTIOUS DISEASES, 1987, 156 (02): : 406 - 407
12345